Dr. Andrew Phipps

Chief Executive Officer
Praxis Scientific, LLC

Education

- Doctor of Veterinary Medicine (1994)
- Ph.D. in Pathobiology (1999)

Core Qualifications

- Integrated Product Development Planning
- Target Product Profile Formulation
- Pre-clinical Study Design
- Toxicology and Safety Pharmacology Studies
- Non-clinical ADME Studies
- Regulatory in the US & EU
- Comparative Medicine and Animal Models
- Program Management
- Board Certification in Microbiology
- Scientific Mentorship

Dr. Phipps co-founded Praxis Scientific, LLC with Dr. Lisa Beth Ferstenberg. He is a biomedical scientist with over 20 years of experience in drug development, comparative medicine, and microbiology. He has extensive preclinical and drug development experience, including nontraditional antimicrobial development and a thorough understanding of the research, development, and licensing process.

Dr. Phipps has held positions at Battelle Memorial Institute (Columbus, OH); The Ohio State University; Sequella Inc. (Rockville, MD); and NeoImmuneTech, Inc. (Rockville, MD.) He provided technical leadership for Battelle's global health, infectious disease, bio-surveillance, and diagnostic research programs for over 10 years. His work focused heavily on Gram negative and positive bacteria, as well as new ways to monitor emerging influenza viruses globally. While at The Ohio State University (2002-2007) he continued his NIAID-funded research into immune correlates of protection for anthrax vaccines, established a BSL-3 aerobiology lab, and worked closely with the Chemistry Department on novel antimicrobial development, in addition to advising graduate students.

During his career, he has contributed to the development of anti-infective agents including sutezolid (an oxazolidinone) and SQ109 (asymmetric diamine) which are in Phase 2 clinical development for drug-resistant tuberculosis and the pre-clinical development of SQ641 (capuramycin) for treatment of *Clostridium difficile* infection.

He has also advised several biotechnology companies on the development of UV4B (immino-sugar) for treatment of Dengue fever (Phase 1) and influenza virus infections (pre-IND), non-clinical studies of DNA vaccines utilizing LAMP-1-tumor antigen fusion proteins, and an IL-7-hyFc fusion protein (pre-IND).

He contributed to the successful identification and development of a biomarker that supported changing the route of administration and schedule for the Anthrax Vaccine Adsorbed (AVA, BioThrax) in 2008 and I also led the team that developed and validated the *in vitro* assay to determine neutralizing titers in support of FDA approval of the cell-cultured smallpox vaccine, ACAM2000, in 2007.

1715 15TH ST NW, Suite 12 | Washington, DC 20009
aphipps@praxisscientific.com